// App-Quantinova.ai

11507 : Tumor infiltrating lymphocytes before and after dual HER2 blockade in HER2-amplified early breast cancer: A TRYPHAENA substudy.

Researchers

Presenter

  • Michail Ignatiadis

Principal Investigators

  • Gert G. Van den Eynden

  • Roberto Salgado

  • Marco Fornili

  • Christine Desmedt

  • Esther Holgado

  • V. A. McNally

  • Astrid Christina Kiermaier

  • Javier Cortes

  • Andreas Schneeweiss

  • Karen Willard-Gallo

  • Elia Biganzoli

  • Christos Sotiriou

Medical Centers

  • Institute Jules Bordet, Brussels, Belgium

  • Institute Jules Bordet, Brussels, Belgium

  • Institute Jules Bordet, Brussels, Belgium

  • University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy

  • Hospital de Madrid, Norte Sanchinarro, Spain

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • University Clinic Heidelberg, Heidelberg, Germany

Locations

  • Italy

  • Spain

  • Germany

  • United Kingdom

  • Switzerland

  • Belgium

Companies

  • Feng Chi Biotech Cor

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Stromal tumor infiltrating lymphocytes

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Carboplatin

  • Trastuzumab

  • Pertuzumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved